Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATORI: Tocilizumab Monotherapy vs Methotrexate in RA
NCT00144521Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2004
- Primary completion
- Aug 2004
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: American College of Rheumatology 20% Improvement at 24 weeks. Started Feb 2004; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00144521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144521.